SCHEMBL2338862

SCHEMBL2338862

CC(=O)CNc1ccc(C(=O)OC(C)(C)C)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.48
RAB9A P51151 3/20 0.48
NPC1 O15118 1/20 0.48
HPGD P15428 1/20 0.48
AGTR1 P30556 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
MAPT P10636 2/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
LMNA P02545 2/20 0.46
CA1 P00915 4/20 0.44
CA2 P00918 4/20 0.44
CA12 O43570 1/20 0.44
CA9 Q16790 1/20 0.44
CA14 Q9ULX7 1/20 0.44
KDM4E B2RXH2 1/20 0.43
STAT3 P40763 2/20 0.43
ABCG2 Q9UNQ0 1/20 0.43
POLB P06746 2/20 0.43
F2 P00734 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23619645 0.83 CA1 (0.47) ALDH1A1RAB9ANPC1HPGDAGTR1
SCHEMBL1206152 0.82 CA1 (0.49) ALDH1A1RAB9ANPC1HPGDAGTR1
SCHEMBL22661373 0.81 POLB (0.50) ALDH1A1RAB9ANPC1HPGDAGTR1
SCHEMBL433863 0.79 ELANE (0.44) ALDH1A1RAB9ANPC1HPGDAGTR1
SCHEMBL9809366 0.79 POLB (0.49) ALDH1A1RAB9ANPC1HPGDAGTR1
SCHEMBL7438829 0.79 ALDH1A1 (0.57) ALDH1A1RAB9ANPC1HPGDAGTR1
SCHEMBL9252978 0.79 POLB (0.46) ALDH1A1RAB9AHPGDLMNACA1
SCHEMBL4286423 0.79 HPGD (0.58) ALDH1A1RAB9ANPC1HPGDSMN1; SMN2
SCHEMBL109451 0.78 CA1 (0.61) ALDH1A1CA1CA2CA12CA9
SCHEMBL22940491 0.78 POLB (0.72) ALDH1A1RAB9ANPC1HPGDAGTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1568688-B1 THERAPEUTIC AGENT FOR RESPIRATORY DISEASE CONTAINING 4-HYDROXYPIPERIDINE DERIVATIVE AS ACTIVE INGREDIENT MOCHIDA PHARM CO LTD (JP) 2011-08-31 EP disclosed
US-7494987-B2 Agent for treating respiratory diseases containing 4-hydroxypiperidine derivative as active ingredient MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2009-02-24 US disclosed
US-20060040985-A1 Therapeutic agent for treating respiratory diseases containing 4-hydroxypiperidine derivative as active ingredient MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2006-02-23 US disclosed
EP-1568688-A1 THERAPEUTIC AGENT FOR RESPIRATORY DISEASE CONTAINING 4-HYDROXYPIPERIDINE DERIVATIVE AS ACTIVE INGREDIENT MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2005-08-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060040985-A1 Therapeutic agent for treating respiratory diseases containing 4-hydroxypiperidine derivative as active ingredient BRD7, RBBP7, NR0B1 ALDH1A1 1424/4885RAB9A 1174/4885NPC1 1066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.